Think Results
Share

Clinical Development Oncology Company Series B-1 Preferred Stock and Warrants

Represented a venture-backed, late-stage clinical development oncology company focused on an epigenetic approach to overcoming the problem of resistance in cancer therapy in connection with its private placement of Series B-1 Preferred Stock and warrants; Represented company in connection with its private placement of Series B-1 Preferred Stock to an Asian venture capital firm; Represented company with its private placement of Series B-1 Preferred Stock to a Russian sovereign wealth backed private equity investor, and current investors; Represented company in connection with several convertible note financing transactions.